

Outlook



AN OUTLOOK
INITIATIVE
WITH DIGILIVE
FOR BUSINESS
LEADERS

INSPIRING
BUSINESS
LEADERS 2021

OVERVIEW OF EDITION

Individuals who rose to be leaders

Every journey is of the soul, and is sole — the two define the purpose of individuals who set out with their singular dreams. Rumi says, “It is your road and yours alone. Others may walk it with you, but no one can walk it for you.” Experiences shaped them and sometimes beat them into becoming larger than life. And thus came about the fruition of their dreams — their companies and products. For these leaders, their organizations are not about profits alone. At heart and in deeds, they are philanthropists who want to make a difference to the world with what they hold in their hands. Businesses are organic entities for them, deeply reflecting the character of the ones in charge.

We bring to you entities who may essentially stand alone but walk together with their people. These are leaders who have given the industry valuable products, but above it all, they have given back to society — by way of their services which variously improve life, or by wealth creation which they fairly and honestly share.

The common thread perhaps is also their method to battle the pandemic, wherein they have stood in support of their employees and the immediate communities, steering the society to safety as best possible. While the world grappled to come to terms with the unprecedented life conditions — the visions and bold thinking of these leaders made them rise to the occasion, adapt and value add. These visionaries are unstoppable and believe that the game has just begun.

CONTENT CONSULTANT

Moneesha Narayan

SPECIAL CORRESPONDENT

Sneha Singh

ASSOCIATION WITH

DIGILIVE

www.Digilive.co

All Rights Reserved ©
Outlook, as to material
published in the feature.
All Rights Reserved.

CONTENT

03

JONATHAN
SHROYER
CEO & CO-Founder

Officium Labs

05

DR. ASHESH KUMAR
CEO & Director

**Paras Biopharmaceuticals
Finland Oy**

07

PRAKASH
CHANDRAN
President Director & CEO

PT Siemens Indonesia

09

FIROZ
THARINIL
Founder and CEO

Westford Education Group

11

ADV. CHANDNI
KAPADIA
Executive Director

GLS University

13

GUS Education

15

CHINTAN PANARA
Co-Founder & Executive Director,
Technology and Strategy

Xpertnest

17

RADHA STIRLING
Founder & CEO

Detained

19

DARSHAN RANA
Chairman & MD

Ersha Agritech Pvt. Ltd.

21

SHWETA PATHAK
Brand Owner

Aakashan Gems & Jewellery

23

VIRENDER SEHWAG

Cricketer

24

ANIL GOPINATHAN
PILLAI
CEO

Airolink Group

26

THOMAS
MUTHOOT

Muthoot Microfin Ltd.

DISCLAIMER: This book is a special marketing initiative of DIGILIVE in partnership with Outlook. While DIGILIVE has taken utmost care to provide with accurate information, readers are advised to independently verify the claims made in the special feature. As DIGILIVE shall not be liable to the veracity of the information in the feature, the readers' discretion is recommended. Outlook editorial team was not involved in this exercise.

Paras Biopharmaceuticals Finland Oy



DR. ASHESH KUMAR
CEO & Director

CREATING BIOLOGICS MANUFACTURING EXCELLENCE & NEW SOLUTIONS FOR RARE & ORPHAN DISEASES

Biologics medicine manufacturing is a very complex process. While biologic medicines offer new solutions for rare & orphan diseases, as well as cure for diseases which are difficult to treat otherwise, the development of medicines for such diseases are exorbitantly expensive. Paras Biopharmaceuticals Finland Oy, as a start-up company in Finland in 2013, decided to take up this formidable task, to develop technology solutions. Paras Biopharmaceuticals Finland Oy team took a deep look at the real problems on why biologics are so expensive. Deep dive into the subject, it was found that biologics (as a medicine) have tremendous manufacturing challenges. The manufacturing process of these medicines is quite often poorly understood, which leads to extreme low qualities making discovery & development and later manufacturing very expensive.

Paras Biopharmaceuticals Finland Oy team made the decision to work on many of the challenges in front of them and fast-forward to 2021, the company today offers un-matched biomufacturing solutions in the industry.

Leading the path of cost-effective biologics medicines production, Paras Biopharmaceuticals Finland Oy has been a sought-after name in the industry. Providing unique solutions for manufacturing complex biologics, the firm is driven by the mission to deliver affordable healthcare while finding effective treatments for rare and orphan diseases.

With its already successful end-to-end biologics CDMO production work, Paras Biopharmaceuticals Finland Oy strives to strengthen its microbially-derived biologics, which also serve to be a significant aspect of the market. It offers best-in-class biosimilar development technologies and recombinant bioprocess enzymes that are instrumental in innovating potential cures for not-so-known diseases or unmet medical needs.

The dedicated professionals working behind the success of the company bring their rich experience to the table and enable a result-driven approach. The highly specialized scientific and

technology management team gets new paradigms in biopharma technology to solve critical bioprocess issues in the most economical and effective manner while maintaining and improving product quality. With a combined experience of close to 60 years in technology and management, the Paras Biopharmaceuticals Finland Oy team holds eloquent process development expertise responsible for driving high-quality results. With a vast experience of developing biosimilars for a decade now, the fanatical individuals continue to drive innovation for the welfare of all while being recognized and accredited with Ph.D.s in Biosciences & Biotechnology.

The scientific tools devised by Paras Biopharmaceuticals Finland Oy

guide in further development of highly complex biologicals, which stand to be a revolutionary change while having a successful track record of treating—specific cancers, respiratory problems & bringing new solutions for inflammatory-related diseases.

THREE KEY AREAS OF EFFECTIVE FUNCTIONING

Paras Biopharmaceuticals Finland Oy has established its expertise in the three critical areas of— development and licensing of biosimilar production technologies, enabling the development of complex proteins from early-stage to large scale, and the development and supply of bioprocess enzymes used routinely in biologics development and production.



While grabbing an effective pace on the development front and strengthening its technological arm, Paras Biopharmaceuticals Finland Oy has paved an excellent way for making healthcare accessible to all. Putting concrete efforts to ensure the cost-effectiveness, high-quality product, and seamless processes being driven, the firm has established a successful way forward.

PARAS BIOPHARMACEUTICALS FINLAND OY' PROPRIETARY & STATE-OF-ART TECHNOLOGIES

The novel technologies built by Paras Biopharmaceuticals Finland Oy boost newer ways of employing combined unique expertise to perform the cleavage of proteins with a fusion partner. Reasoning to this cutting-edge innovation, the need for expensive cleavage enzymes in production is prevented. In-depth protein purification knowledge put forward by the firm provides the perfect solutions to realize higher product yields. This has also been instrumental in achieving an authentic product with cost-effectiveness.

Paras Biopharmaceuticals Finland Oy has developed a number of manufacturing technology platforms within the host organisms, including *E. coli*, *Pichia pastoris*, and *Saccharomyces cerevisiae*. This innovation is taken forward with their process optimization that has been vital in enhancing the production of biopharmaceuticals without the need to change the clones. The easy multiplication of these biologics is also accompanied by lower production costs and a robust process that is seamlessly scaled up.

The entire industry has witnessed highly expensive solutions for the manufacturing of biologic medicines. This is primarily because of the inconsistent and ineffective

NobleClev™

The most eye-grabbing aspect of this effective technology is its significant reduction of wastage in the processing of biologics, with a prominent rise in the overall yields. This has also been imperative in bringing down the production cost while developing authentic biologics.

With an amalgamation of high specificity and activity of processing, Paras Biopharmaceuticals has been able to hit the right spot for an efficient outcome to be generated.

Diabrid™

This advanced technology facilitates a higher expression of the therapeutic proteins in a manner that enhances the quality and bio-effectiveness of the molecules. This also boasts post-production protocols for the expression of recombinant therapeutic proteins and therapeutic peptides, and that's precisely what makes this proprietary technology by Paras Biopharmaceuticals Finland Oy immensely unique.

Biomultifold™

Biomultifold™ is an immensely effective technology that allows expression levels of multiple therapeutic proteins per litre of fermentation to be achieved. This has enhanced an economic system for generating recombinant proteins and their scale-up production. It is one of the most suitable technologies employed for the large-scale production of biosimilars, especially for taking it to a commercial scale.

Cytofold StructQuant™

Offering the twin benefit of having the cost-effectiveness as presented by the expression of *E. coli* while matching the high-yields obtained in cytoplasmic expression—Cytofold StructQuant™ is a high-end proprietary technology of Paras Biopharmaceuticals Finland Oy.

Developed for the high-level expression of homogeneous folded disulfide bonds containing proteins in the cytoplasm of *E. coli*, the technology produces biologics having maximal biological activity, unlike the ones obtained with the expressions in the cytoplasm.

Paras Biopharmaceuticals Finland Oy' Proprietary Technologies Include:

technologies that work behind them. Paras Biopharmaceuticals Finland Oy steps right in and presents a revolutionary way to disrupt the technological front to produce desirable results.

PARAS BIOPHARMACEUTICALS FINLAND OY' BIOLOGICS PRODUCTION FACILITY IN FINLAND

Paras Biopharmaceuticals Finland Oy has a fully equipped biologics production facility in Finland for the production of recombinant therapeutic products in microbial systems. The state-of-art biologics production plant includes a total floor area of 25,000 ft² and a classified cleanroom of 4,300 ft². Other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying.

Paras Biopharmaceuticals Finland Oy has a strong pipeline of Biologics & Biosimilars in Osteoporosis, Rheumatoid Arthritis, Oncology and Metabolic Diseases.

For more information, please see the company pipeline: <http://www.parasbiopharma.com/biosimilars/biosimilars.php>

COMPANY AND THE TEAM

The dedicated team behind Paras Biopharmaceuticals Finland Oy is driven by the sole vision to provide an economical solution for expensive medicines as part of its internal pipeline. Keeping the industry trends in view, the microbial-derived biologics hold an extremely small segment of the entire market and thus provides Paras Biopharmaceuticals Finland Oy with a unique advantage with a high growth rate and lesser competition.

'Paras' is attributed to 'best' in Finnish, but its connotations are often expanded to ultimate, optimal, and pre-eminent. Along with all the members on board, the firm strives to live up to this mapping and continue to grease the wheels for moving forward. While allowing efficiency and quality to walk together, Paras

Biopharmaceuticals Finland Oy marches forward with an ever-growing result-oriented mindset.

Paras Biopharmaceuticals Finland Oy is able to discuss, manage and coordinate all the aspects associated with their work with the effective development of a 'teamwork' culture. This has enabled the firm to drive innovative solutions and disrupt the technology for the better!

THE MAN BEHIND IT ALL

The company has bagged several international awards in Europe & the USA along with receiving immense appreciation for their quality of development. Dr. Ashesh Kumar, CEO and Director: Biologics & Licensing has been an effective catalyst in leading the company and bringing it to this level of success.

With an extensive experience of more than two decades, Dr. Kumar has successfully developed and out-licensed biosimilar technologies for scale-up production of biologics and biosimilars in Europe and Asia. He continues to play an instrumental role in ensuring the smooth functioning of the facility.

Paras Biopharmaceuticals Finland Oy is on its road to monumental innovations that are certain to change the face of biologics and its manufacturing. With their latest developments and upcoming plans, one is sure to see path-breaking products coming their way!

PARAS BIOPHARMACEUTICALS FINLAND OY – REACHING OUT WORLDWIDE.

